Abstract
Background Malaria remains one of the leading causes of death in Sub-Saharan Africa (SSA). The scoping review mapped evidence in research on existing studies on malaria genome-wide association studies (GWAS) in SSA.
Methods A scoping review was conducted to investigate the extent of malaria studies in SSA under GWAS. The review followed the methodology for scoping reviews developed by Arksey and O’Malley, including identification of research problems, searching for relevant studies, selecting studies, charting data, collating, summarizing, and reporting the findings. Data from relevant studies were collected and synthesized using Excel and Zotero software. The data collected included information on the author, the years of study, the countries of study, the research areas of interest, and the study designs used.
Results Of an initial pool of over 2000 articles retrieved from four databases, namely Google Scholar, PubMed, Scopus, and Web of Science, 569 were retained. After applying the inclusion-exclusion criteria, 99 articles were found to be relevant. Most of these studies (n=25, 60%) used a case-control study design, while the rest used cross-sectional, cohort, longitudinal, family-based, and retrospective designs. These studies were conducted between 2000 and 2023, with a significant increase observed in 2011. Most studies were carried out in Kenya (n = 25), Gambia (n = 17), Cameroon (n = 15), Ghana (n = 12), and Tanzania (n=11), primarily exploring genetic variants associated with malaria susceptibility, resistance, and severity.
Conclusion Many case-control studies in Kenya and Gambia reported genetic variants in malaria susceptibility, resistance, and severity. Few articles were systematic reviews and scoping reviews. GWAS on malaria is scarce in SSA and even fewer studies are model-based. Consequently, there is a pressing need for more genome-wide research on malaria in SSA.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
